F. Andrew Dorr

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

Howard A. Burris, Malcolm J. Moore, John Sahl Andersen et al. · Journal of Clinical Oncology · 1997 · 5.8K citations

A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma

E. David Crawford, Mario A. Eisenberger, David G. McLeod et al. · New England Journal of Medicine · 1989 · 1.5K citations

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer.

Walter M. Stadler, Timothy M. Kuzel, Bruce J. Roth et al. · Journal of Clinical Oncology · 1997 · 346 citations

Metastatic Urothelial Cancer, Urology, Oncology +14

A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation

David Rinaldi, John G. Kuhn, Howard A. Burris et al. · Cancer Chemotherapy and Pharmacology · 1999 · 174 citations

Medicinal Chemistry, Pharmaceutical Science, Preclinical Drug Evaluation +10

Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial

Howard A. Burris, Malcolm J. Moore, John Sahl Andersen et al. · Journal of Clinical Oncology · 2023 · 165 citations